News
TECH
59.54
-6.16%
-3.91
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Simply Wall St · 14h ago
Bio-Techne Names New Diagnostics and Spatial Biology President
TipRanks · 1d ago
Exosome Diagnostics Reports Year-End Results With Sales and Net Income Figures for 2025
Reuters · 1d ago
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors
MarketWatch · 1d ago
Bio-Techne Names Steve Crouse President of Diagnostics and Spatial Biology Segment
Reuters · 1d ago
*Bio-Techne: McManus to Remain for a Period of Time to Support Smooth Transition >TECH
Dow Jones · 1d ago
*Bio-Techne Matt McManus, Pres of Diagnostics and Spatial Biology Segment, to Transition From Role >TECH
Dow Jones · 1d ago
BIO-TECHNE ANNOUNCES CHANGES TO ITS LEADERSHIP TEAM
Reuters · 1d ago
*Bio-Techne Appoints Steve Crouse Pres, Diagnostics and Spatial Biology Segment >TECH
Dow Jones · 1d ago
Press Release: Bio-Techne Announces Changes to its Leadership Team
Dow Jones · 1d ago
What Are Wall Street Analysts' Target Price for Bio-Techne Stock?
Barchart · 1d ago
Is It Time To Reassess Bio-Techne (TECH) After Years Of Share Price Weakness?
Simply Wall St · 3d ago
Weekly Report: what happened at TECH last week (0202-0206)?
Weekly Report · 3d ago
Nasdaq, S&P, Dow futures rise ahead of key macroeconomic reports
Seeking Alpha · 3d ago
Bio Techne (TECH) Margin Compression To 6.7% TTM Tests Bullish Growth Narratives
Simply Wall St · 6d ago
Bio-Techne Is Maintained at Overweight by Wells Fargo
Dow Jones · 6d ago
Bio-Techne Price Target Raised to $76.00/Share From $70.00 by Wells Fargo
Dow Jones · 6d ago
Wells Fargo Maintains Overweight on Bio-Techne, Raises Price Target to $76
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Medical Facilities (OtherMFCSF), Bio-Techne (TECH) and Verastem (VSTM)
TipRanks · 6d ago
BIO-TECHNE CORPORATION <TECH.O>: WELLS FARGO RAISES TARGET PRICE TO $76 FROM $70
Reuters · 6d ago
More
Webull provides a variety of real-time TECH stock news. You can receive the latest news about Bio-Techne Corp through multiple platforms. This information may help you make smarter investment decisions.
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.